Pharmacologic therapeutic window of pramiracetam demonstrated in behavior, EEG, and single neuron firing rates.
Following oral or intravenous administration, a representative cognition activator drug, pramiracetam sulfate, is shown to have a pharmacologic therapeutic window at three different levels of study: learned behavior, gross EEG activity of the frontal cortex and hippocampus, and firing rate of single hippocampal neurons.
D000284:Administration, Oral; D000818:Animals; D001522:Behavior, Animal / Q000187:drug effects*; D004569:Electroencephalography; D004594:Electrophysiology; D007275:Injections, Intravenous; D007858:Learning / Q000187:drug effects; D008297:Male; D009474:Neurons / Q000187:drug effects* / Q000502:physiology; D010830:Physostigmine / Q000494:pharmacology; D011759:Pyrrolidines / Q000627:therapeutic use*; D051381:Rats; D011916:Rats, Inbred F344
D011759:Pyrrolidines; C038438:pramiracetam; D010830:Physostigmine